#FDA issues updated information on Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL). Know and consider the risks. https://go.usa.gov/xQxxs   #MedicalDevice

#FDA issues updated information on Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL). Know and consider the risks. https://go.usa.gov/xQxxs  #MedicalDevice
Source: Food and Drug Adminstration (FDA): CDRHNew - Category: Medical Devices Authors: Source Type: news

Related Links:

Hodgkin lymphoma (HL) is one of the most curable malignancies. Despite its effectiveness, chemotherapy is often associated with adverse events (AEs) such as nausea, anorexia, and impairment of general well-being. Our objective was to assess the extent of medical cannabis use among HL patients and evaluate its efficacy in controlling chemotherapy-related AEs. Patterns of medical cannabis use and efficacy were evaluated using physician-completed application forms, medical files, and patient-completed questionnaires, for all consecutive adult HL patients treated at the Tel-Aviv Medical Center between June 2010 and November 20...
Source: Acta Haematologica - Category: Hematology Source Type: research
The objective of this review is to correlate radiological findings of silicone-induced granuloma of breast implant capsule (SIGBIC) from breast MRI (BMRI) scans and complementary findings of ultrasound (US) and positron emission tomography (PET) scan, and its histology originated from surgical breast implant capsulectomy. To make this correlation possible, we divided SIGBIC into three radiological findings: (1) intracapsular SIGBIC, (2) SIGBIC with extracapsular extension, and (3) mixed SIGBIC associated with seroma. Our experience demonstrates histological-radiological correlation in SIGBIC diagnosis. Knowledge of these f...
Source: Journal of Immunology Research - Category: Allergy & Immunology Tags: J Immunol Res Source Type: research
British Journal of Haematology, EarlyView.
Source: British Journal of Haematology - Category: Hematology Authors: Source Type: research
ConclusionsThis case emphasizes the uncommon adverse effect of the anaplastic lymphoma kinase-targeted therapy alectinib causing acute renal failure manifesting as acute tubular necrosis. Recognition of alectinib nephropathy requires a thorough drug history and knowledge of risk factors that lessen its margin of safety at therapeutic ingestions. Frequent monitoring of renal functions and early nephrology referral significantly reduce the mortality and morbidity of these patients.
Source: Journal of Medical Case Reports - Category: General Medicine Source Type: research
Publication date: Available online 17 October 2018Source: Biochimica et Biophysica Acta (BBA) - General SubjectsAuthor(s): Sana Batool, Kimon V. Argyropoulos, Roksana Azad, Precious Okeoma, Hasan Zumrut, Sanam Bhandari, Rigzin Dekhang, Prabodhika R. MallikaratchyAbstractNucleic Acid Aptamers (NAAs) are a class of synthetic DNA or RNA molecules that bind specifically to their target. We recently introduced an aptamer termed R1.2 against membrane Immunoglobulin M (mIgM) expressing B-cell neoplasms using Ligand Guided Selection (LIGS). While LIGS-generated aptamers are highly specific, their lower affinity prevents aptamers f...
Source: Biochimica et Biophysica Acta (BBA) General Subjects - Category: Biochemistry Source Type: research
Condition:   Non Hodgkin Lymphoma Intervention:   Drug: Tenalisib, Sponsor:   Rhizen Pharmaceuticals SA Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Cancer (Colon Cancer, Breast Cancer, Lymphoma, Multiple Myeloma);   Elderly;   Antineoplastic Agents;   Cardiotoxicity Interventions:   Other: Intensive cardiovascular monitoring;   Other: No intervention Sponsors:   Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León;   IBSAL-Instituto de Investigación Biomédica de Salamanca, Fundación IECSCYL-IBSAL;   Instituto de Salud Carlos III Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   CD20 Positive;   Mantle Cell Lymphoma Interventions:   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Ibrutinib;   Drug: Methotrexate;   Biological: Rituximab;   Drug: Venetoclax;   Drug: Vincristine Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Non Hodgkin Lymphoma Intervention:   Drug: Tenalisib, Sponsor:   Rhizen Pharmaceuticals SA Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Cancer (Colon Cancer, Breast Cancer, Lymphoma, Multiple Myeloma);   Elderly;   Antineoplastic Agents;   Cardiotoxicity Interventions:   Other: Intensive cardiovascular monitoring;   Other: No intervention Sponsors:   Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León;   IBSAL-Instituto de Investigación Biomédica de Salamanca, Fundación IECSCYL-IBSAL;   Instituto de Salud Carlos III Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Lymphoma | Medical Devices | Plastic Surgery